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The regulatory networks of differentiation programs
have been partly characterized; however, the molec-
ular mechanisms of lineage-specific gene regulation
by highly similar transcription factors remain largely
unknown. Here we compare the genome-wide
binding and transcription profiles of NEUROD2-
mediated neurogenesis with MYOD-mediated myo-
genesis. We demonstrate that NEUROD2 and
MYOD bind a shared CAGCTG E box motif and
E box motifs specific for each factor: CAGGTG for
MYOD and CAGATG for NEUROD2. Binding at
factor-specific motifs is associated with gene tran-
scription, whereas binding at shared sites is associ-
ated with regional epigenetic modifications but is
not as strongly associated with gene transcription.
Binding is largely constrained to E boxes preset in
an accessible chromatin context that determines
the set of target genes activated in each cell type.
These findings demonstrate that the differentiation
program is genetically determined by E box
sequence, whereas cell lineage epigenetically deter-
mines the availability of E boxes for each differentia-
tion program.
INTRODUCTION
The family of basic-helix-loop-helix (bHLH) transcription factors
regulates differentiation programs in numerous cell types. For
example, the Neurod family regulates neuronal differentiation,
the Myod family regulates skeletal muscle differentiation, and
the E-proteins regulate B and T cell differentiation and also func-
tion as heterodimer partners for both Myod and Neurod family
members (Berkes and Tapscott, 2005; Chae et al., 2004; Murre,
2005). Each of these factors binds to a motif containing the coreDeveCANNTG sequence, termed an E box. Although some additional
sequence preferences have been described for each factor
(Blackwell and Weintraub, 1990; Seo et al., 2007), the degrees
of shared and specific binding relative to differentiation
programs have not been described. Since the bHLH family
evolved by duplication and divergence, the maintenance of
a common core E box sequence suggests the possibility of
shared sites among family members that might have a functional
role in gene regulation and/or other aspects of differentiation.
However, the large differences in the transcriptional programs
of neurons, muscles, and T cells strongly indicate that each
factor has evolved mechanisms for factor-specific gene
regulation.
Other studies of transcription factor families suggest several
mechanisms of achieving factor-specific gene regulation within
a family of highly related transcription factors. In several cases,
transcriptional activity and site-specific binding are regulated
separately. For instance, members of the NF-kB family were
shown to bind at the same sequences, but demonstrated
sequence specific transcriptional activity (Leung et al., 2004).
Similarly, the glucocorticoid receptor (GR) will bind to many
similar sequences, but transcriptional activation depends on
a DNA sequence-specific allosteric activation of the bound GR
(Meijsing et al., 2009). Therefore, hormone receptor families
and NF-kB families of transcription factors might achieve
gene-specific regulation by regulated activity at binding sites
shared by multiple family members. The ETS family of transcrip-
tion factors also has sites bound by many different family
members; however, factor-specific transcription appears to be
achieved by a subset of binding sites with sequence variations
that favor a specific family member, as well as binding of cofac-
tors specific to the transcriptional program (Hollenhorst et al.,
2007, 2011). In the case of the ETS family, the binding sites
shared bymultiple family members are associated with constitu-
tively expressed genes, suggesting that factor binding corre-
sponds to local gene activation for both the shared and factor-
specific binding sites.
In addition to binding site sequence, several recent studies
indicate that chromatin structure limits access for factor bindinglopmental Cell 22, 721–735, April 17, 2012 ª2012 Elsevier Inc. 721
Figure 1. NEUROD2 Binds Genome-wide in P19 Cells Differentiated into Neurons
(A) Differentiation of P19 cells by expression of NEUROD2. Immunostaining of P19 cells before (top panels) and 72 hr after (bottom panels) transduction with
NEUROD2 lentivirus (green, Tuj1 antibody; red, NEUROD2 antibody; blue, DAPI).
(B) NEUROD2 antibody is specific for NEUROD2. Immunoprecipitation of 35S-labeled in vitro translated bHLH proteins relative to 10% input (lane 1) with either
nonspecific immunoglobulin G (IgG) (lane 2) or two different NEUROD2 antibodies (lanes 3 and 4).
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Table 1. GO Categories of NEUROD2 Upregulated Genes Identified by Expression Array
GO ID p Value Odds Ratio Count Size Term
GO:0007275 3.2E30 4.14 120 1,141 multicellular organismal development
GO:0048858 8.6E19 7.25 39 192 cell projection morphogenesis
GO:0031175 5.3E18 7.86 35 163 neuron projection development
GO:0045202 5.8E15 6.01 35 200 synapse
GO:0023046 1.6E13 2.44 109 1,476 signaling process
GO:0007411 2.8E12 12.77 17 54 axon guidance
GO:0005509 3.6E12 3.18 57 561 calcium ion binding
GO:0048856 5.0E12 6.03 27 176 anatomical structure development
GO:0007155 5.5E12 5.18 31 202 cell adhesion
GO:0009653 8.8E12 5.07 31 214 anatomical structure morphogenesis
GO:0007268 4.6E11 6.95 22 110 synaptic transmission
GO:0030424 7.2E10 7.61 18 83 axon
GO:0007399 5.2E09 6.99 17 95 nervous system development
GO:0030054 1.0E08 4.24 26 196 cell junction
See also Table S1.
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protein 1 (AP1) facilitates open chromatin and GR receptor
binding, essentially presetting the chromatin context for
response to GR activation (Biddie et al., 2011; Hakim et al.,
2011; John et al., 2011). Factor binding can also be prevented
at accessible sites by the competitive binding of factors, such
as CBF1 occluding accessible sites and preventing the binding
of PHO4 in yeast (Zhou and O’Shea, 2011). The role of chromatin
accessibility can also be demonstrated in a developmental
context in Drosophila, where it limits the sites accessible to tran-
scription factors and correlates with local gene transcription (Li
et al., 2011; Thomas et al., 2011).
Within this context, we have examined the genome-wide
binding and transcriptional activity of NEUROD2 in P19 cells
and MYOD in mouse embryonic fibroblasts (MEFs). NEUROD2
expression converts P19 cells to neurons and MYOD expres-
sion converts MEFs to skeletal muscle cells, whereas
NEUROD2 does not induce neurogenesis in MEFs, nor does
MYOD induce myogenesis in P19 cells. We determined that
NEUROD2 and MYOD bind a shared E box motif, RRCAGCTG,
and E boxes with motifs specific to each factor: CAGATG for
NEUROD2 and CAGGTG for MYOD. Binding at the
NEUROD2-specific motif was associated with transcription of
the neuronal differentiation program, whereas binding at the
shared sites was associated with regional epigenetic modifica-
tions but not regional gene transcription, and a similar trend was
observed for MYOD-specific motifs. In each cell type, binding is
largely constrained to E boxes preset in an accessible chro-
matin context and lineage-restricted differentiation reflects
differences in E box accessibility. These findings demonstrate(C) NEUROD2 binding is associated with, but does not reliably predict, gene upr
before and 72 hr after transduction with NEUROD2 lentivirus. NEUROD2 peak hei
domain of gene TSSs is plotted against the log2-fold change in mRNA express
activation. The blue trend line in the scatter plot was computed with the loess loca
75th percentiles, the width represents the size of the data set, the dot is the media
bounded by 1.5 times IQR (25th and 75th interquartile range) from the box.
See also Figure S1.
Devethat the differentiation program is genetically encoded by the
location of the factor-specific E boxes and that cell lineage
establishes the set of E boxes in an accessible chromatin
context.
RESULTS
NEUROD2 ChIP-Seq Demonstrates Genome-wide
Binding and Regional Histone Acetylation
We have previously shown that the pluripotent mouse cell line
P19 can be converted to neurons by the exogenous expression
of NEUROD2 (Farah et al., 2000). Transduction of P19 cells with
a NEUROD2-expressing lentivirus achieved nearly complete
conversion to neurons (Figure 1A). Expression array analysis
identified the upregulation of 532 genes and downregulation of
278 genes (see Table S1 available online). Gene set enrichment
analysis (GSEA) showed that upregulated genes were associ-
ated with Gene Ontology (GO) categories involving neuron
development and differentiation (Table 1).
To identify NEUROD2 binding sites, we used two different
rabbit polyclonal antibodies that specifically pull down
NEUROD2 (Figure 1B) and performed chromatin immunoprecip-
itations in P19 cells transduced with the NEUROD2 lentivirus fol-
lowed by high throughput sequencing (ChIP-Seq). Reads with
a unique match in the mouse genome were extended to a total
length of 200 nucleotides (nt), which was the estimated average
fragment size, and the number of overlapping reads at each
position in the genome was computed to generate peak heights
for NEUROD2 or the control ChIP samples (P19 cells ChIPed
with preimmune serum; see Experimental Procedures). Theegulation. NEUROD2 ChIP-Seq and microarrays were performed in P19 cells
ght (y axis, square root transformation) of binding sites located within the CTCF
ion (x axis) in smooth scatter plot (left) and boxplot (right) binned by level of
l regression method; in the boxplot, the vertical bounds represent the 25th and
n value, and the whisker extends to the extreme value (minimum or maximum),
lopmental Cell 22, 721–735, April 17, 2012 ª2012 Elsevier Inc. 723
Table 2. GO Categories of All Annotated Genes Possessing NEUROD2 Peaks within ±2 kb of the TSS
GO ID p Value Odds Ratio Count Size Term
GO:0031175 2.3E10 2.88 70 158 neuron projection development
GO:0048858 3.6E10 2.57 82 197 cell projection morphogenesis
GO:0048856 4.7E10 2.65 76 185 anatomical structure development
GO:0007399 9.3E09 3.06 52 115 nervous system development
GO:0030424 1.3E08 4.39 34 62 axon
GO:0003779 3.9E07 2.07 82 224 actin binding
GO:0030036 2.8E06 3.89 26 50 actin cytoskeleton organization
GO:0007050 4.1E06 4.08 24 45 cell cycle arrest
GO:0022603 5.2E06 2.59 42 100 regulation of anatomical structure morphogenesis
GO:0051960 5.4E06 2.37 49 123 regulation of nervous system development
GO:0007242 1.3E05 2.09 58 159 intracellular signaling cascade
GO:0016055 5.4E05 2.54 34 82 Wnt receptor signaling pathway
GO:0007411 5.4E05 2.87 28 63 axon guidance
GO:0004725 5.9E05 2.52 34 82 protein tyrosine phosphatase activity
See also Table S2.
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correlation coefficient of 0.9 (Figure S1A), and the data from
the two antisera were pooled for further analysis. The small
number of regions enriched in the preimmune ChIP control
were subtracted from our analyses.
To identify NEUROD2 binding sites, we compared the false
discovery rate (FDR) at various read coverage cutoffs in anti-
NEUROD2 and preimmune samples (Figure S1B). Using
a conservative cutoff of a p value < 1010 corresponding to
23 reads or more (FDR < 2.43 108), 35,042 peaks were iden-
tified in the anti-NEUROD2 samples (Table S2). Although the
region ±2 kb around a transcription start site (TSS) contained
the highest density of binding regions (Figure S1C), the majority
of peaks were located in introns and intergenic regions, the latter
defined as regions more than 10 kb away from any known tran-
scripts (Table S2).
We used three different approaches to assign a peak to a gene
(or genes): (1) binding within the immediate region of the gene,
defined as 2 kb upstream from the TSS to 2 kb downstream of
the polyadenylation site; (2) binding within the domain estab-
lished by the two CTCF binding regions (SRX 000540, from the
NCBI Sequence Read Archive) that flank the TSS for each
gene; and (3) binding ±2 kb from a TSS. With these approaches,
40%of 18,054 annotated genes were bound by NEUROD2; 48%
of the annotated genes had at least one TSS with a NEUROD2-
bound region (or regions) within the flanking CTCF domain; and
19% of genes had a TSS with NEUROD2 bound in the ±2 kb
region. GSEA on all annotated genes possessing NEUROD2
peaks ±2 kb from the TSS demonstrated enrichment for GO
categories such as neurogenesis and neuronal differentiation
and development (Table 2). However, although there is a trend
for genes upregulated by NEUROD2 to be bound by NEUROD2
either within 2 kb of the TSS (data not shown) or within the CTCF
domain flanking the TSS (Figure 1C), themajority of genes bound
by NEUROD2 do not change in expression. Therefore, NEU-
ROD2 binding does not reliably predict transcriptional regulation
of the closest TSS.724 Developmental Cell 22, 721–735, April 17, 2012 ª2012 Elsevier ICharacteristics of NEUROD2 Binding Sites
To determine the sequence characteristics of NEUROD2 binding
sites, we examined the E box sequences found in the 200-nt
region centered under the NEUROD2 peak summit. Within these
regions, 98% of peaks contained at least one canonical E box
(CANNTG), and 80% of peaks contained an E box within 20 nt
of the peak summit. A strong sequence preference was
observed for the central dinucleotides within these E boxes,
with a high frequency of GA and GC E boxes at NEUROD2 peaks
(Figure S2A). Focusing on the nearest E box to the peak summit,
47% contained the motif GA, and 33% were GC. Within the
entire 200-nt window, 65% of peaks contained a GA and 50%
contained a GC E box. Further refinement of the motif model
indicates that the sequence preference also extended to the
flanking nucleotides, with a G or A at the 2 and 1 positions,
a strong absence of T at the 1 position, and a preference for
G at the +1 position, yielding a consensus NEUROD2 binding
site of RRCAGMTGG (Figure 2A). ChIP of the endogenous
NEUROD2 in P19 cells differentiated to neurons by treatment
with retinoic acid followed by quantitative PCR at 10 loci
confirmed that the endogenousNEUROD2bindsChIP-Seq-iden-
tified siteswith either CAGCTGorCAGATGE boxes (Figure S2B).
To determine other potential factors influencing NEUROD2
binding, we performed a de novo motif search for all motifs en-
riched within an area spanning 200 nt around the peak summit
and compared this to randomly selected regions in the genome
of similar GC content. In addition to enrichment for E boxes, we
also observed an increased frequency of the AATCAAT PBX
motif (Figure 2B). PBX proteins have previously been demon-
strated to be important during retinoic acid-mediated neuronal
differentiation of P19 cells (Qin et al., 2004). We also observed
enrichment for other homeobox-like motifs with the consensus
sequences DGATTA, TAATKA, and CAATTA. Numerous
homeobox proteins expressed in P19 cells, such as LHX2,
PITX2, OTX2, and EN2, have roles in neuronal development
and neural lineage specification (Acampora et al., 1999; Evans
and Gage, 2005; Koenig et al., 2010; Subramanian et al.,nc.
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binding sites for POU domain factors, one of which, Brn2, has
recently been described to assist in the direct conversion of
fibroblasts to neurons (Pang et al., 2011; Vierbuchen et al., 2010).
NEUROD2 and MYOD Bind to Shared and Private
E Boxes that Correlate with Common and Distinct
Genomic Binding Sites
The preferred E box for NEUROD2 (CAG[C/A]TG) overlaps with
the preferred E box for MYOD (CAG[C/G]TG), derived from
a similar analysis of MYOD binding sites in mouse muscle cells
and embryonic fibroblasts converted to muscle by transduction
with MYOD (Cao et al., 2010) (Figure 2A). This suggested that
there might be a common set of binding sites with a GC core
as well as a set of NEUROD2-specific (GA core) and MYOD-
specific (GG core) sites. To evaluate this further, we estimated
the E box binding affinities of NEUROD2 and MYOD with
in vitro gel shift competition assays. While both bHLH proteins
are capable of binding each of these E boxes in vitro, there is
a clear binding preference of NEUROD2 for the GA E box and
of MYOD for the GG E box (Figure 2C). Conversely, we observed
an approximately equivalent affinity between NEUROD2 and
MYOD for the GC E box (data not shown).
To determine if these shared (GC) and private (GA for
NEUROD2 and GG for MYOD) E box motifs correlated with
shared and private binding, we compared ChIP-Seq peaks from
NEUROD2 in P19 cells andMYOD in cells differentiated into skel-
etal muscle. For the MYOD binding profile, we used MEFs con-
verted to skeletal muscle by lentiviral expression of MYOD. This
binding profilewas similar to both the previously publishedprofile
in differentiated C2C12 mouse myoblasts and primary muscle
cells (A.P.F., Z.Y., W.L.R., R.C.G., and S.J.T., unpublished data).
The total number of NEUROD2 peaks in P19 cells ranged from
35,000 (p < 1010) to 72,000 (p < 105), and the number of
MYOD peaks in MEFs ranged from 67,000 to 124,000 at
the same p value thresholds (Table S2). To evaluate the degree
of peak overlap, we organized peaks into bins based on their
rank according to peak p values and plotted the degree of over-
lap within corresponding bins representing the top 30,000 peaks
for bothNEUROD2 andMYOD.Overall, therewas20%overlap
of the top 30,000 NEUROD2 and MYOD peaks (Figure 2D). As
anticipated, we observed very little overlap between NEUROD2
andMYOD binding at peaks centered on aGA or on GGE boxes:
We found that 8.8% of GA peaks bound by NEUROD2 were also
bound by MYOD, whereas 12.5% of GG peaks bound by MYOD
were also bound by NEUROD2. In contrast, 40% of GC peaks
bound byNEUROD2were also bound byMYOD (Figure 2E), indi-
cating that the majority of shared NEUROD2 and MYOD binding
occurs at GC E boxes, while binding at private E boxes is not
shared.
NEUROD2 and MYOD Private Sites Are Associated with
Differentiation Programs
The presence of shared and private NEUROD2 andMYODpeaks
suggested the possibility of shared and private gene expression
profiles. While NEUROD2 and MYOD are presumed to control
neuron and muscle specific genes, respectively, a direct
comparison of their regulated genes has not yet been performed,
to our knowledge. Based on our expression array data, thereDevewere 990 genes upregulated by MYOD in MEFs and 532 genes
upregulated by NEUROD2 in P19 cells, with 67 genes upregu-
lated by both factors (all compared to the same cell type not ex-
pressing MYOD or NEUROD2, with a 2-fold change cutoff).
We determinedwhether these private and shared transcription
programs correlated with private or shared binding by assessing
the presence of private or shared ChIP-Seq peaks within the
promoter regions (±2 kb of the TSS) of genes expressed in
neurons, muscle, or both (Figure 3A). The private genes specifi-
cally activated by NEUROD2 and not MYOD were enriched for
NEUROD2 private peaks (i.e., bound by NEUROD2 and not
MYOD). The differential binding was significantly correlated
with the presence of a NEUROD2-preferred position weight
matrix (PWM) (color coded in Figure 3A). Similarly, the genes
activated by MYOD and not NEUROD2 were enriched for
MYOD private peaks bound to a MYOD-preferred PWM.
The shared genes that were activated by both MYOD and
NEUROD2 were associated with shared peaks (i.e., MYOD and
NEUROD2 peaks in the same location as demonstrated by their
distribution along the 45 axis of the scatter plot comparing
MYOD and NEUROD2 binding within the promoter regions of
these genes; see ‘‘shared’’ panel in Figure 3A). While in many
instances this shared binding appeared to be associated with
NEUROD2 or MYOD private E boxes (note the green and red
points along the 45 axis), assessment of individual promoters
demonstrated the presence of both shared GC E boxes and
private E boxes within close proximity of the peak summits (Fig-
ure S2C). The set of genes regulated by both MYOD and
NEUROD2 included many factors involved in signaling, vesicle
transport, and other components of cell differentiation (Table
S3). It is notable that nearly 10% of this set of genes regulates
the activity of bHLH factors, either by directly interacting with
bHLH factors (Id1, Id2, Hes6, and Cbfa2t3) or by binding to
E box sequences (Znf238,Zeb1). In addition, the shared program
was enriched in Notch signaling pathway genes (5/67 = 7%:
Notch1, Dll1, Dner, Hes6, and Megf10) and genes critical for
cell differentiation (Cdk5r1, Pou4f1,Mllt11, and Rb1). Therefore,
bothMYODandNEUROD2bind a common set of sites and regu-
late a shared program of cell differentiation that includes critical
genes in the Notch, cell cycle, and differentiation pathways.
To further assess the relative importance of the private and
shared E box motifs for gene regulation, we asked whether
binding at a private or a shared motif better correlated with
regional gene expression. For this analysis, we defined shared
and private sites by the presence of a shared or private peak
that also contained a shared or private motif with a high PWM
score and assigned these sites to a gene if they were within
2 kb of a TSS. Genes bound by NEUROD2 at private sites
showed greater upregulation than genes bound by NEUROD2
at shared sites (Figure 3B), despite similar peak heights in both
groups (data not shown). Genes bound byMYOD at private sites
also showed a trend toward higher activation compared to genes
bound by MYOD at shared sites, although it was not as signifi-
cant as for NEUROD2 (Figure 3B). GSEA analysis on the genes
associated with the NEUROD2 or MYOD private sites, whether
transcriptionally regulated or not, demonstrated enrichment for
categories associated with neurogenic and myogenic develop-
ment, respectively, while the genes associated with shared sites
were associated with general cellular and metabolic processeslopmental Cell 22, 721–735, April 17, 2012 ª2012 Elsevier Inc. 725
Figure 2. NEUROD2 and MYOD Possess Shared and Private Binding Sites
(A) E boxmotif enrichment at NEUROD2 andMYODpeaks (a and d) demonstrates central dinucleotide and flanking sequence preferences that consist of a factor-
specific motif (b and e) and a shared motif (c and f).
(B) Motifs enriched (see Experimental Procedures) under NEUROD2 peaks in P19 cells compared to background. All motifs posses z values > 5 based on
a logistic regression model, with an approximate p value of <107 (ratio: enriched/depleted ratio of motifs; fg.frac, bg.frac: fraction of foreground/background
sequences that contain at least one motif occurrence).
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and MYOD sites are more important for the regulation of
lineage-specific genes.
To determine whether the apparently greater transcriptional
activity of the NEUROD2 private sites can be partly attributed
to the private E box motif, we tested the ability of NEUROD2 to
activate paired E box reporter constructs that differed only in
the core dinucleotides of the E box sequence. NEUROD2 prefer-
entially activated a reporter construct driven by paired
NEUROD2 private E boxes (GA) compared to MYOD private
E boxes (GG) or shared E boxes (GC) (Figure 3C). Many bHLH
factors, such as MYOD and NEUROD2, require paired binding
sites for transcriptional activation (or an E box paired with
another factor binding site) because cooperative interactions
stabilize the weak binding to an isolated E box (Weintraub
et al., 1990). Combining one GA E box with an E box that
NEUROD2will not bind (CG core that is bound by theMYC family
but not NEUROD2 or MYOD) or that binds relatively weakly (GG
core) resulted in significantly decreased activity compared to the
paired GA E boxes, whereas pairing a single GA E box with a GC
E box had substantially more activity than the paired GC
E boxes, although less than the paired GA E boxes. Therefore,
it appears that a GC E box can facilitate the activity of a GA
E box, possibly by facilitating cooperative binding. Although
MYOD activated the reporter with MYOD private E boxes more
than with shared E boxes, the difference was not as dramatic
as for NEUROD2, and MYOD also activated a reporter with the
NEUROD2 private E boxes (Figure 3C, bottom). Although spec-
ulative, it will be interesting to determine whether additional
flanking motifs at MYOD sites will confer a greater distinction
in the activities of private and shared sites.
Previously, we demonstrated that MYOD binding was associ-
ated with regional histone 4 acetylation (Cao et al., 2010). To
further understand the role of the shared binding sites, we
compared histone acetylation changes specifically at shared
and private sites. We observed enhanced acetylation occurring
equivalently at both the privateGA and the sharedGCNEUROD2
bindingsites (Figure3D). In addition, bindingofNEUROD2atboth
of these sets of sites induces a bimodal histone distribution that
has been suggested to indicate a functional binding site (Hoffman
et al., 2010) (Figure 3E). Therefore, although relatively few genes
are commonly regulated by both MYOD and NEUROD2, their
shared genome-wide binding at GC E boxes results in wide-
spread alterations of nucleosome positioning and modification.
NEUROD2 and MYOD Binding Is Determined by
Chromatin Accessibility and Cofactor Motifs
While there was 40% overlap between the GC binding profiles
of NEUROD2 in P19 and MYOD in MEF, a significant proportion(C) NEUROD2 andMYOD bind with higher affinity to their private E box sequences
containing identical flanking sequences and either a MYOD-preferred (probe A), o
shown above each lane. An asterisk indicates E12 homodimer. Bottom: EMSA
preferred (probe D) E box with flanking sequence from a natural site.
(D) Comparison of the top 30,000 peaks bound by NEUROD2 in P19 cells (x axis)
the origin, bins represent the top 3,000 peaks, then the top 6,000 peaks, etc., as d
by both NEUROD2 and MYOD (see Experimental Procedures).
(E) NEUROD2 and MYOD shared E box sequence correlates with shared binding
MYOD in MEFs restricted to the top 30,000 peaks centered on a GC E box dem
See also Figure S2.
Deveof these E boxes were not shared. To assess chromatin acces-
sibility at all GC E boxes, we exposed nuclei from P19 cells
and MEFs to PvuII, which cleaves CAGCTG sites, and
sequenced the cleaved sites, amodification of NA-Seq (Gargiulo
et al., 2009) (see Experimental Procedures and Figure S3A). We
ranked GC E boxes based on their relative accessibilities to PvuII
prior to introduction of NEUROD2 or MYOD.
P19 cells and MEFs had 50% overlap of the top 100,000
accessible GC E boxes (Figure S3B), indicating cell-type differ-
ences in chromatin accessibility. To investigate the extent to
which chromatin accessibility determines factor binding, we
restricted our analysis to GC E boxes with a high PWM score
for MYOD and NEUROD2 in their flanking nucleotides and,
thus, goodbindingmotifs for eitherMYODorNEUROD2.Notably,
E boxes with very low nuclease accessibility in P19 cells or MEFs
had very fewNEUROD2 orMYODpeaks, respectively, indicating
that nuclease inaccessible E boxes were also inaccessible to
these factors (Figure 4A). E boxes that were accessible to the
nuclease, on the other hand, showed a broad range of binding.
We looked for motifs that might distinguish bound sites from
unbound sites within nuclease-accessible regions. Compared
to accessible but unbound sites, NEUROD2 bound sites in P19
cells were enriched 1.5-fold for the MEIS motif and 1.7- to 1.8-
fold for motifs of other homeodomain factors (Figure 4B). Acces-
sible sites bound by MYOD in MEFs were enriched 1.4-fold for
the MEIS motif. In addition to these factor motifs, the sites that
were accessible and bound were enriched for good consensus
E boxes with a higher average PWM compared to accessible
and unbound sites (Figure 4C). There was also a higher average
total number of E boxes at NEUROD2 and MYOD bound sites
compared to unbound sites within PvuII-accessible areas (Fig-
ure 4D). Together, these results indicate that, in addition to chro-
matin accessibility, good PWM E boxes, additional adjacent
E boxes, and motifs for other potential cooperative factors
modulate the binding of NEUROD2 in P19 cells and MYOD in
MEFs. These data are consistent with prior studies showing
that a MEIS-containing complex cooperates with MYOD binding
at the Myogenin promoter (Berkes et al., 2004).
For both MYOD and NEUROD2, accessible but unbound sites
were enriched for the ZEB1 motif. As noted earlier, both MYOD
and NEUROD2 activate the expression of Zeb1 and Znf238, both
factors that bind E boxes and suppress activity of MYOD and/or
NEUROD2 (Postigo and Dean, 1997; Yokoyama et al., 2009).
Therefore, both MYOD and NEUROD2 activate the expression of
factors that might prevent their access to a subset of E boxes.
Cell Lineage Determines Binding and Gene Regulation
Our results suggest that private sites correlate with, and likely
determine, the private genes activated by NEUROD2 and, to. Top: EMSA using translated NEUROD2 or MYOD and E12mixed with probes
r NEUROD2-preferred (probe B) E box and competed with cold A or B probe as
using probes containing either a MYOD-preferred (probe C) or NEUROD2-
and MYOD in MEFs (y axis) demonstrates20% overlap of binding sites. From
etermined by peak height rank. Colors represent the proportion of sites bound
sites. Comparison of binding site overlap between NEUROD2 in P19 cells and
onstrates 40% overlap.
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Figure 3. The Neurogenic and Myogenic Programs Correlate with NEUROD2 and MYOD Binding to Private Sites
(A) Scatter plot of private and shared NEUROD2 and MYOD peaks within the promoter regions (±2 kb from the TSS) of genes upregulated by NEUROD2 in P19
cells (ND.P19), MYOD in MEFs (MD.MM), or upregulated by both (shared). The number of reads is represented in square root transformation. Sites are further
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Determinants of Myogenesis and Neurogenesis
728 Developmental Cell 22, 721–735, April 17, 2012 ª2012 Elsevier Inc.
Developmental Cell
Determinants of Myogenesis and Neurogenesisa lesser extent, by MYOD. To determine whether cell lineage
constrains differentiation potential by site accessibility, we
compared gene expression and binding profiles for MYOD ex-
pressed in P19 cells and NEUROD2 expressed in MEFs. Neither
expression of MYOD in P19 cells nor NEUROD2 in MEFs by len-
tiviral delivery resulted in myogenesis or neurogenesis. This is
consistent with prior studies showing that <3% of P19 cells
transfected with MYOD differentiate into muscle and that
NEUROD2 expression alone is insufficient to convert fibroblasts
to neurons (Skerjanc et al., 1994; Yoo et al., 2011). However,
despite the absence of differentiation, there remained a signifi-
cant degree of genome wide binding and gene regulation by
these factors.
There were 51,004 NEUROD2 peaks in MEFs and 21,695
MYOD peaks in P19 cells at a threshold p-value of 1010 (Table
S2). Comparing NEUROD2 and MYOD peaks across cell types,
we observed30% overlap for the top 30,000 NEUROD2 peaks
between P19 cells and MEFs and a similar overlap between the
top 30,000 MYOD peaks in both cell types (Figure 5D). A total of
605 genes was upregulated by NEUROD2 in MEFs, and only 83
genes overlapped with genes upregulated by NEUROD2 in P19
cells. The majority of genes uniquely upregulated by NEUROD2
in MEFs were associated with GO categories not involved in
neural development but rather extracellular and membrane
components (Table S1). For MYOD, 134 genes were upregulated
in P19 cells and 68 overlappedwith genes upregulated byMYOD
in MEFs. In contrast to NEUROD2 in MEFs, these genes were
associated with a number of GO terms related to muscle devel-
opment, potentially representing a partial activation of the
myogenic program (Table S1). Overall, however, the majority of
the transcriptional programs of neurogenesis and myogenesis
were not activated when MYOD or NEUROD2 was expressed
in the opposite cell type, and this correlated with decreased
binding at promoter-proximal sites near these genes (Fig-
ure S3C). A motif analysis again identified the PBX motif (AT-
CAAT) as enriched in genes upregulated by NEUROD2 and not
MYOD in P19 cells, and RUNX (ACCACA) at genes upregulated
by MYOD and not NEUROD2 in MEFs (Figure S3D), again impli-
cating PBX and RUNX as cell-type specific cofactors. However,
further analysis of ChIP-Seq peaks did not demonstrate a prefer-
ential enrichment for these motifs at peaks near regulated genes
compared to peaks near unchanged genes (data not shown),characterized by PWM score (see Experimental Procedures): green, NEUROD2 p
were excluded.
(B) Sites occurring within 2 kb of a TSS plotted against the fold change in gene ac
peak height; x axis: log2-fold change in gene expression). (c) Box plot of fold cha
and MYOD. There is greater gene activation associated with private sites based o
Using a threshold of 2-fold change in expression, 21.1% of genes associated wi
associated with shared sites (p = 8.2e-9 per Fisher’s exact test). For MYOD, 25.1
23.5% associated with shared peaks (p = 0.67), whereas 11.8% of genes asso
associated with a shared site (p = 0.03).
(C) Reporter constructs containing paired E boxes with the indicated central nucle
(bottom). *p < 0.05 by t test compared to vector without E box insertion (pGL3).
(D) Scatter plot of peak height derived from native ChIP-Seq for acetyl-histone 4 in
NEUROD2-induced change in acetylation at shared sites; ND.private, acetylati
NEUROD2 in P19 cells. Number of reads are shown in square root transformatio
(E) The y axis represents the number of raw reads from native ChIP-Seq for acetyl-
nucleotide position centered on the E box closest to the summit of either the p
acetylation in P19 cells at baseline (bottom panels), and a significant increase in
See also Table S3.
Devesuggesting these factors might primarily influence binding but
not transcriptional activation.
Chromatin Accessibility Is the Major Determinant of
Lineage-Specific Binding
To determine whether chromatin accessibility in each cell type is
the major determinant of binding pattern for each factor, we
compared the binding profile of NEUROD2 in P19 and MEFs
and the profile of MYOD in P19 andMEFs at all sites or at acces-
sible sites. When expressed in the same cell type, where acces-
sibility is the same for both factors, there was 30% overlap
between MYOD and NEUROD2 when comparing the top
30,000 peaks grouped by rank (Figure 5A), which included
both private and shared sites. Restricting this comparison to
the top 10,000 peaks with a good consensus MYOD and
NEUROD2 shared E box (RRCAGCTGG), however, significantly
increased the overlap to 70% for MYOD and NEUROD2 peaks
within the same cell type (Figure 5B). Further restricting the anal-
ysis to the shared E box peakswith high accessibility by the PvuII
assay showed a nearly complete overlap of MYOD and
NEUROD2 binding within the same cell type (Figure 5C).
As stated previously, when comparing NEUROD2 or MYOD
binding profiles between different cell types, there was 30%
overlap for all sites (see Figure 5D). This degree of overlap
increased only modestly to 40% on restricting the analysis to
the top 10,000 peaks with a consensus shared E box
(RRCAGCTGG; Figure 5E). However, further restriction of the
analysis to consensus E boxes with high nuclease accessibility
scores in both cell types increased the overlap to 80%–90%
(Figure 5F). These findings indicate that the preexisting chro-
matin structure and associated binding site accessibility are
major determinants of MYOD and NEUROD2 binding in the
different cell types.
DISCUSSION
Our results are consistent with those of prior studies on the
specific activity of individual members of a family of transcription
factors and suggest an emergingmodel of how related transcrip-
tion factors maintain some common functions and yet achieve
specific transcriptional activity. Similar to studies on the ETS
family of factors, MYOD and NEUROD2 bind to a shared E boxrivate site; red, MYOD private site; black, shared site. Genes with multiple TSS
tivation for (a) NEUROD2 and (b) MYOD. (y axis: square root transformation of
nge in gene activation (log2) comparing private and shared sites for NEUROD2
n aWilcoxon rank sum test for NEUROD2 (p < 106) and for MYOD (p = 0.027).
th NEUROD2 private sites have fold changeR2, compared to 5.4% of genes
% of genes associated with private peaks have fold changeR2 compared to
ciated with private sites have a fold change R8 compared to 6.3% of genes
otideswere transfected into P19 cells with NEUROD2 (top) or MEFswithMYOD
Error bars represent 1 SD.
P19 cells prior to (x axis) and after (y axis) transductionwith NEUROD2. Shared,
on at NEUROD2 private sites; MD.private, acetylation at sites not bound by
n.
histone 4, divided by strand (blue, + strand; red, strand). The x axis represents
rivate (left half) or shared (right half) NEUROD2 peaks. There is little histone
histone acetylation after differentiation with NEUROD2 (top panels).
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Figure 4. Chromatin Accessibility Is Necessary but Not Sufficient for NEUROD2 and MYOD Binding
(A) Scatter plots comparing (a) NEUROD2 binding sites in P19 cells and (b)MYODbinding sites inMEFswith PvuII nuclease accessibility at these sites. NEUROD2
andMYOD peak height (y axis) and the normalized accessibility of PvuII sites (x axis; see Experimental Procedures for calculation) are represented in square root
transformation. Only PvuII sites in the context of goodMYOD andNEUROD2motif matches with PWMscoresR14 are included. Blue line is the fitted loess curve.
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Figure 5. NEUROD2 and MYOD Binding between Cell Types Is Strongly Determined by Chromatin Accessibility
(A) Comparison of the top 30,000 peaks bound by NEUROD2 and MYOD in the same cell type (left, P19 cells; right, MEFs) demonstrates a 30% overlap of
peaks. From the origin, bins represent the top 3,000 peaks, then the top 6,000 peaks, etc., as determined by peak height rank. Color scale represents the
percentage of peaks bound by both NEUROD2 andMYOD (see Experimental Procedures). Bins are presented with their corresponding p values for peak height.
(B) Restriction of the comparison in (A) to the top 7,000–10,000 peaks containing a RRCAGCTGG E box.
(C) Further restriction of the comparison in (B) to the top 1,500–3,000 peaks containing a RRCAGCTGGE box with a high nuclease accessibility score (normalized
value > 2).
(D) Comparison of the top 30,000 peaks bound by NEUROD2 in both P19 and MEFs (left) or MYOD in both P19 and MEFs (right).
(E) Restriction of the comparison in (D) to the top 7,000–10,000 peaks containing a RRCAGCTGG E box.
(F) Further restriction of the comparison in (E) to the top 1,500–3,000 peaks and containing a RRCAGCTGG E box with a high nuclease accessibility score.
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the NEUROD2 private sites—and, to a lesser extent, at the
MYOD private sites—is correlated with transcriptional activation
of their respective differentiation programs, which is similar to
the reported association of factor-specific binding sites with
genes regulated by individual members of the ETS family. In
contrast, binding at the NEUROD2 or MYOD shared sites does(B) Motif enrichment analysis comparing bound and unbound sites within PvuII-
enriched/depleted ratio of motifs; fg.frac, bg.frac: fraction of foreground/backgro
(C) Plot of E box PWM (y axis) for (a) NEUROD2 and (b) MYOD bound and unboun
bound regions.
(D) Plot of the number of E boxes at PvuII-accessible regions either bound or unb
number of E boxes located within the 200 bp window of a PvuII-accessible site. T
See also Figure S3.
Devenot show the same degree of regional gene activation. In addi-
tion, NEUROD2 showed stronger transcriptional activation of
a reporter driven by its private E boxes, compared to the shared
E box motifs, and MYOD showed the same trend. This does not
appear secondary to affinity, as peak height was similar at
private and shared sites (data not shown). These findings indi-
cate that motif sequence might confer a level of transcriptionalaccessible areas for (a) NEUROD2 in P19 cells and (b) MYOD in MEFs (ratio:
und sequences that contain at least one motif occurrence).
d sites within PvuII-accessible regions demonstrates a higher average PWM at
ound by (a) NEUROD2 in P19 cells or (b) MYOD in MEFs. Colors represent the
he x axis is the frequency of sites containing the depicted number of E boxes.
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sequence-specific allosteric activation described for the GR
receptor (Meijsing et al., 2009).
The E box motif for NEUROD2 is similar to the consensus
binding site identified for the related neurogenic bHLH factor
ATOH1 (RMCAKMTGKY) in a ChIP-Seq study from mouse cere-
bellum (Klisch et al., 2011). The central dinucleotide preferences
are similar to NEUROD2, whereas ATOH1 appears to have
a palindromic flanking nucleotide preference different from
NEUROD2, although this might result from the motif algorithm
method used. It is interesting that a subset of flanking nucleo-
tides are enriched at ATOH1 E boxes in enhancers of genes ex-
pressed in dorsal interneurons (AMCAGMTG) (Lai et al., 2011),
suggesting E box specificity might have a role in neuronal
subtype gene regulation; however, functional differences were
not observed in this study.
The biological role of the NEUROD2 and MYOD shared sites
remains unclear. Although we do not yet know the biological
significance of these shared sites, the induction of a bimodal
H4 acetylation signal is similar to the criteria developed for bio-
logically functional binding sites for several transcription factors
(FOXA2, PDX1, and HNF4A) in liver development (Hoffman et al.,
2010), and it is interesting to speculate that the alteration of
histone modifications at many thousands of sites genome-
widemight have a yet unknown biological function that is distinct
from regional transcription, perhaps related to nuclear compart-
ments and/or architecture (Lieberman-Aiden et al., 2009).
It is interesting that MYOD and NEUROD2 both induce the
expression of Znf238 and Zeb1. ZNF238 binds to a consensus
sequence that includes the CAGATG E box, whereas the ZEB1
site includes the CAGGTG E box. In skeletal muscle cells,
ZNF238 has been shown to inhibit the expression of the Id
genes, and its binding appears to prevent MYOD activity at the
same region (Yokoyama et al., 2009). Similarly, ZEB has been
shown to bind the E box in the IgH enhancer and prevent its acti-
vation in non-B cells (Genetta et al., 1994). Therefore, MYOD and
NEUROD2 initiate the expression of factors that can suppress
their activities at a subset of E boxes, possibly limiting the genes
regulated by each factor. This is consistent with the transient
activation of Id genes by MYOD and might be a general method
of suppressing the early programs initiated by MYOD and
NEUROD2.
It is interesting that NEUROD2 activates approximately the
same number of genes in MEFs as in P19 cells but there is
very little overlap in the set of regulated genes. Similarly,
MYOD activated different sets of genes with partial overlap in
P19 cells and MEFs. Therefore, both are active transcription
factors in both cell types, but the cell type determines the target
genes that will be activated. Our nuclease access studies indi-
cate that chromatin structure is a major determinant of binding
site accessibility in the different cell lineages. This is consistent
with the studies showing that nuclease accessibility predicts
GR binding (Biddie et al., 2011; John et al., 2011). However,
accessibility is not the only determinant of binding at a particular
site. Motif analysis determined that additional E boxes were
associated with both NEUROD2 and MYOD peaks and that
PBX and homeobox-like motifs are associated with NEUROD2
peaks. This study, together with our prior MYODChIP-Seq study
(Cao et al., 2010), identified MEIS and RUNX motifs with MYOD732 Developmental Cell 22, 721–735, April 17, 2012 ª2012 Elsevier Ipeaks. Therefore, accessibility is important for the spectrum of
sites available for MYOD and NEUROD2, whereas other factor
motifs may influence the degree of binding at particular acces-
sible sites. Although associated with NEUROD2 or MYOD
binding, we did not find an association of these motifs specifi-
cally with regulated genes (data not shown), suggesting a role
in binding rather than transcriptional activation. This is in contrast
to the strong association of RUNX1 motifs near TAL1 binding
sites in T cells (Palii et al., 2011), where RUNX appears to play
a direct role in TAL1 binding and gene regulation. It is also impor-
tant to note that, in our study, we are identifying associated
motifs and have not directly identified the factors binding at
these motifs.
In this study, and in our prior MYOD ChIP-Seq study (Cao
et al., 2010), we identified tens of thousands of bound sites. In
both studies, neither peak height nor p value accurately pre-
dicted peaks that were associated with a regulated gene. An
important consideration in this study is that we have forced the
expression of both MYOD and NEUROD2 by lentiviral transduc-
tion. Our previous publication on endogenous MYOD binding in
C2C12 mouse muscle cells and MEFs virally transduced with
MYOD showed a 90% similarity in peak location. In addition,
comparison of the lentiviral MYOD binding in MEFs with endog-
enous MYOD in C2C12 cells and primary mouse myotubes
shows a similar level of concordance (Z. Yao, unpublished
data), indicating that the lentiviral transduction produces an
accurate representation of the binding of endogenous MYOD,
possibly because of limiting amounts of the endogenous
E-protein dimerization partner, which would also be true for
NEUROD2.
In summary, both NEUROD2 and MYOD bind to tens of thou-
sands of sites genome-wide. Factor-specific transcriptional
programs appear to be encoded, at least in part, by private
E boxes that drive the transcriptional programs of neurons and
muscles in P19 cells and MEFs, respectively, whereas many
thousands of shared sites are associated with histone acetyla-
tion but not as strongly associated with regional gene transcrip-
tion, particularly for NEUROD2. Cell lineage determines the
accessibility of the sites and constrains the transcriptional
response by each factor. The fact that NEUROD2 and MYOD
activate the expression of large numbers of genes that are not
normally a part of their differentiation program when expressed
in a different lineage (i.e., NEUROD2 in MEFs and MYOD in
P19 cells) indicates that lineage transitions, such as epithelial-
to-mesenchymal transition, could profoundly alter the transcrip-
tional program of these or other transcription factors.EXPERIMENTAL PROCEDURES
Microarray and GO Analysis
Total RNA samples were collected in triplicate from undifferentiated and differ-
entiated P19 cells and MEFs, and labeled cDNA was made per Affymetrix
protocol. Samples were hybridized on Affymetrix Mouse 430 2.0 Expression
Arrays. We analyzed the microarrays using Bioconductor simpleaffy and
limma package. Differentially expressed genes were chosen with an FDR
cutoff of 0.05 and a fold change cutoff of 2. The trend line in Figure 1C was
computed using a loess local regression method. We performed GO analysis
using the Bioconductor GOstats package. Association studies of peak binding
affinity and gene expression were performed as previously described (Cao
et al., 2010).nc.
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ChIP was performed as previously described (Cao et al., 2010). Briefly, 108
cells were fixed in 1% formaldehyde for 11 min, quenched with glycine, lysed,
and then sonicated to generate final DNA fragments of 150–600 bp. The
soluble chromatin was diluted 1:10 and precleared with a 1:1 Protein A:G slurry
for 2 hr at 4C. Chromatin was mixed with antibody overnight at 4C and then
Protein A:G beads for 2 hr. Beads were washed and decrosslinked overnight
for 16 hr in 1% SDS, 0.1 M NaHCO3, and 70 mg Proteinase K. ChIP samples
were validated by qPCR and prepared for sequencing per the Illumina Sample
Preparation protocol, with two modifications: (1) DNA fragments of 150–
300 bp were selected at the gel selection step; and (2) 21 cycles of PCR
were performed at the amplification step instead of 18. For the controls, we
used P19 cells ChIPed with preimmune serum and MEFs ChIPed with
MYOD antibody. We performed native ChIP with micrococcal nuclease
digestion per a published protocol (Brand et al., 2008). Mononucleosomes
were isolated at the final gel selection step. All samples were sequenced
with the Illumina Genome Analyzer II and IIx platforms.PvuII Endonuclease Accessibility Assay
Cells (5 3 106) were trypsinized and washed once in reticulocyte suspension
buffer (RSB: 10 mM Tris, pH 7.4, 10 mM NaCl, 5 mM MgCl2), followed by re-
suspension in lysis buffer (RSB + 0.1% NP-40) at a final concentration of
1.5 3 106 cells per milliliter and incubation on ice for 10 min. Nuclei were pel-
leted and washed in lysis buffer, followed by resuspension in 200 ml of 13NEB
Buffer 2, the addition of 40 units of PvuII (NEB) per 106 nuclei, and incubation at
37C for 30 min. STOP buffer (200 ml) (0.6 M NaCl, 20 mM Tris, pH 7.4, 10 mM
EDTA, 1% SDS, 2 mg/ml proteinase K) was added, and the reaction was incu-
bated at 37C overnight. Genomic DNA was isolated with QIAGEN DNeasy
spin columns. DNA (5 mg) was used for labeling, beginning with the addition
of an ‘‘A’’ tail to the blunt ends generated by PvuII digestion using Klenow
3-50 exo (NEB). After purification through MinElute columns (QIAGEN),
custom-designed biotinylated adapters with a ‘‘T’’ overhang and an EcoRV
site immediately upstream of the ‘‘T’’ (purchased from IDT) were ligated on
to the ‘‘A’’-tailed ends with Quick Ligase (NEB). After purification (QIAGEN),
DNA was fragmented to 150–350 bp with a Diagenode Bioruptor (low ampli-
tude, 30 s/cycle, 30 cycles). Biotinylated fragments were enriched with Strep-
tavidin-conjugated Dynabeads (Invitrogen), and DNA was released from the
beads by digestion with EcoRV for 1 hr at 37C. Fragments were subsequently
purified and labeled for sequencing as described earlier.ChIP-Seq Peak Calling and Significance Inference
We extracted sequences using the GApipeline software. Reads mapping to
the X and Y chromosomes were excluded from our analysis. Reads were
aligned with MAQ and BWA to the mouse genome (mm9). We discarded
duplicate sequences to minimize affects of PCR amplification. Each read
was extended in the sequencing orientation to a total of 200 bases to infer
the coverage at each genomic position. We performed peak calling with an
R package (pending submission to Bioconductor), developed in house,
which models background reads by a negative binomial distribution. The
negative binomial distribution can be viewed as a continuous mixture of
Poisson distribution where the mixing distribution of the Poisson rate is
modeled as a Gamma prior. This prior distribution is used to capture the vari-
ation of background read density across the genome. The parameters of the
negative binomial distribution were estimated by fitting the truncated distri-
bution on the number of nucleotides with coverage 1–3, to avoid the problem
of inferring effective genome size excluding the nonmappable regions and to
eliminate contamination of any foreground signals in the high coverage
regions. We also fit separate model parameters based on the binned GC
content of the flanking sequence, which, based on our observations, heavily
correlates with background read density. Therefore, the significance of the
peaks is determined not only by peak height but also by the GC content
of the flanking sequence. We used control ChIP-Seq samples (preimmune
serum in P19 cells and MYOD antibody in MEFs) to eliminate statistically
significant peaks likely due to artifact. We removed all peaks that overlap
with the peaks in the control sample at a p value cutoff of 105 and required
all remaining peaks to have a much more significant p value (103) than in the
control sample.DeveMotif Analysis
We used a discriminative de novo motif discovery tool described previously
(Cao et al., 2010; Palii et al., 2011) to find motifs that distinguish foreground
and background sequence data sets. To find motifs enriched under ChIP-Seq
peaks, we selected background sequences using random genomic regions
sampled with similar GC content and distance to TSS. Themotif z values follow
a normal distribution if there is no distinction between foreground and back-
ground sequences. To learn a PWMmodel, we used the output motif instances
from the motif discovery tool as the seed to initialize the iterative expectation-
maximization (EM) refinement process, which is essentially the same as
MEME. In some cases, the motifs are extended iteratively as long as there is
sequencepreference in theflanking region, and refined in thesameEMprocess.
ChIP-Seq Sample Comparison
Comparison across cell types is difficult, as it is unclear how to set up a fair
comparison baseline due to the differences in the sample preparation
protocol, total number of reads, foreground/background reads distribution,
and, in some cases, even the underlying genome sequences. Here, we adopt
a rank-based paradigm to compare ChIP-Seq samples of different transcrip-
tion factors and cell types while still taking the peak p value significance into
account. We rank all peaks by their p values and group ranks into bins of
3,000 (i.e., the top 3,000 peaks, then the top 6,000 peaks, etc.). Then we
compute the fraction of top x peaks in one sample that overlap with the top
y peaks in another sample, where x and y vary from 3,000 to 30,000 and
yR x. For the top 20,000 peaks overlapping between NEUROD2 in P19 and
MYOD in MEFs, the average degree of overlap was 529 bp (69% of peak
width), with 90% of peaks overlapping more than 369 bp. For comparison of
overlap at specific E boxes, we estimate the overlap of peaks containing
a GC E box underneath the summit. The same procedure is then used, except
that the peaks are ranked among all GC-containing subsets.
PvuII and Histone 4 Acetylation Data Analysis
The reads at a typical PvuII site with GC E box can be divided into four cate-
gories, based on whether they are from the 50 end or 30 end of the fragments
and whether they are at the cleaved ends of the fragments or the random soni-
cated ends.We define the accessibility by combining reads both at the cleaved
ends and at the sonicated ends within 200 bp from the cleavage site and
normalizing this value by dividing it with the median value of the reads at all
PvuII sites. These two components are comparable for the bulk of the data.
For the histone acetylation data, we used 500 bp sliding windows across the
genome and used the number of reads falling into each window to assess
the genome-wide acetylation pattern. Then we evaluated the histone acetyla-
tion within the 500 bp window centered at the NEUROD2 or MYOD binding
sites to study the association between the two. To assess the degree of change
in chromatin state in MEFs and P19 cells with or without NEUROD2 or MYOD,
we used the DESEQ Bioconductor package to detect changes in accessibility
or histone acetylation under two conditions. For the PvuII nuclease accessi-
bility data, we used replicates for a better estimate of variance. For the histone
acetylation data without replicates, we used the pooled variance estimates.
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